Mitogen-activated protein kinases

Natalia Bogatcheva, Alexander D. Verin

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The family of mitogen-activated protein kinases (MAPKs) comprises several protein kinases, united by their ability to phosphorylate serine or threonine residues followed by proline; therefore, these often are termed proline-directed protein kinases. Another characteristic feature of the MAPKs is the presence of specific phosphoacceptor site(s) in the regulatory loop of the enzyme catalytic core. HISTORY AND EVOLUTION MAPKs were originally named after the protein they were discovered to phosphorylate in insulin-or growth factor–treated mammalian cells, namely microtubule-associated protein 2 (MAP-2). Later, with the realization that virtually all mitogens lead to the rapid activation of these protein kinases, the enzymes were renamed mitogen-activated protein kinases. Now, it is clear that MAPK function is not limited to the initially described induction of cell division, but also extends to control over cell differentiation, survival, motility, and gene expression. Because MAPKs orchestrate the physiological processes fundamental for both single-and multicellular organisms, it is not surprising that homologous enzymes are found in eukaryotes from budding yeast to mammals (1). The deletion of certain MAPK genes in mammals leads to early embryonic lethality, proving the essential role of MAPK signaling in the developmental processes (Table 81–1). MITOGEN-ACTIVATED PROTEIN KINASE STRUCTURE AND FUNCTION To date, five different groups of MAPKs are known in mammals. Enzymes within groups are generated from a number of gene products; additional isoforms were shown to derive from the alternative splicing of pre-mRNAs (12). Mammalian MAPKs include extracellular-signal-regulated protein kinase (ERK)1/2; p38 MAPKs (α, β, γ, and δ); c-jun N-terminal kinases (JNK1, JNK2, JNK3);ERK5, also known as BMK1(13); and the recently identified ERK3 subfamily, comprising the products of two genes, MAPK4 and MAPK6 (14).

Original languageEnglish (US)
Title of host publicationEndothelial Biomedicine
PublisherCambridge University Press
Pages737-745
Number of pages9
ISBN (Print)9780511546198, 0521853761, 9780521853767
DOIs
StatePublished - Jan 1 2007
Externally publishedYes

Fingerprint

Mitogen-Activated Protein Kinases
Mammals
Protein Kinases
Genes
Enzymes
Proline-Directed Protein Kinases
Cells
Physiological Phenomena
Saccharomycetales
Microtubule-Associated Proteins
Mitogen-Activated Protein Kinase 3
JNK Mitogen-Activated Protein Kinases
RNA Precursors
Alternative Splicing
p38 Mitogen-Activated Protein Kinases
Threonine
Eukaryota
Mitogens
Proline
Gene expression

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Bogatcheva, N., & Verin, A. D. (2007). Mitogen-activated protein kinases. In Endothelial Biomedicine (pp. 737-745). Cambridge University Press. https://doi.org/10.1017/CBO9780511546198.082

Mitogen-activated protein kinases. / Bogatcheva, Natalia; Verin, Alexander D.

Endothelial Biomedicine. Cambridge University Press, 2007. p. 737-745.

Research output: Chapter in Book/Report/Conference proceedingChapter

Bogatcheva, N & Verin, AD 2007, Mitogen-activated protein kinases. in Endothelial Biomedicine. Cambridge University Press, pp. 737-745. https://doi.org/10.1017/CBO9780511546198.082
Bogatcheva N, Verin AD. Mitogen-activated protein kinases. In Endothelial Biomedicine. Cambridge University Press. 2007. p. 737-745 https://doi.org/10.1017/CBO9780511546198.082
Bogatcheva, Natalia ; Verin, Alexander D. / Mitogen-activated protein kinases. Endothelial Biomedicine. Cambridge University Press, 2007. pp. 737-745
@inbook{2c9b5554b7df43bf8238ef0a36ccbbdf,
title = "Mitogen-activated protein kinases",
abstract = "The family of mitogen-activated protein kinases (MAPKs) comprises several protein kinases, united by their ability to phosphorylate serine or threonine residues followed by proline; therefore, these often are termed proline-directed protein kinases. Another characteristic feature of the MAPKs is the presence of specific phosphoacceptor site(s) in the regulatory loop of the enzyme catalytic core. HISTORY AND EVOLUTION MAPKs were originally named after the protein they were discovered to phosphorylate in insulin-or growth factor–treated mammalian cells, namely microtubule-associated protein 2 (MAP-2). Later, with the realization that virtually all mitogens lead to the rapid activation of these protein kinases, the enzymes were renamed mitogen-activated protein kinases. Now, it is clear that MAPK function is not limited to the initially described induction of cell division, but also extends to control over cell differentiation, survival, motility, and gene expression. Because MAPKs orchestrate the physiological processes fundamental for both single-and multicellular organisms, it is not surprising that homologous enzymes are found in eukaryotes from budding yeast to mammals (1). The deletion of certain MAPK genes in mammals leads to early embryonic lethality, proving the essential role of MAPK signaling in the developmental processes (Table 81–1). MITOGEN-ACTIVATED PROTEIN KINASE STRUCTURE AND FUNCTION To date, five different groups of MAPKs are known in mammals. Enzymes within groups are generated from a number of gene products; additional isoforms were shown to derive from the alternative splicing of pre-mRNAs (12). Mammalian MAPKs include extracellular-signal-regulated protein kinase (ERK)1/2; p38 MAPKs (α, β, γ, and δ); c-jun N-terminal kinases (JNK1, JNK2, JNK3);ERK5, also known as BMK1(13); and the recently identified ERK3 subfamily, comprising the products of two genes, MAPK4 and MAPK6 (14).",
author = "Natalia Bogatcheva and Verin, {Alexander D.}",
year = "2007",
month = "1",
day = "1",
doi = "10.1017/CBO9780511546198.082",
language = "English (US)",
isbn = "9780511546198",
pages = "737--745",
booktitle = "Endothelial Biomedicine",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - Mitogen-activated protein kinases

AU - Bogatcheva, Natalia

AU - Verin, Alexander D.

PY - 2007/1/1

Y1 - 2007/1/1

N2 - The family of mitogen-activated protein kinases (MAPKs) comprises several protein kinases, united by their ability to phosphorylate serine or threonine residues followed by proline; therefore, these often are termed proline-directed protein kinases. Another characteristic feature of the MAPKs is the presence of specific phosphoacceptor site(s) in the regulatory loop of the enzyme catalytic core. HISTORY AND EVOLUTION MAPKs were originally named after the protein they were discovered to phosphorylate in insulin-or growth factor–treated mammalian cells, namely microtubule-associated protein 2 (MAP-2). Later, with the realization that virtually all mitogens lead to the rapid activation of these protein kinases, the enzymes were renamed mitogen-activated protein kinases. Now, it is clear that MAPK function is not limited to the initially described induction of cell division, but also extends to control over cell differentiation, survival, motility, and gene expression. Because MAPKs orchestrate the physiological processes fundamental for both single-and multicellular organisms, it is not surprising that homologous enzymes are found in eukaryotes from budding yeast to mammals (1). The deletion of certain MAPK genes in mammals leads to early embryonic lethality, proving the essential role of MAPK signaling in the developmental processes (Table 81–1). MITOGEN-ACTIVATED PROTEIN KINASE STRUCTURE AND FUNCTION To date, five different groups of MAPKs are known in mammals. Enzymes within groups are generated from a number of gene products; additional isoforms were shown to derive from the alternative splicing of pre-mRNAs (12). Mammalian MAPKs include extracellular-signal-regulated protein kinase (ERK)1/2; p38 MAPKs (α, β, γ, and δ); c-jun N-terminal kinases (JNK1, JNK2, JNK3);ERK5, also known as BMK1(13); and the recently identified ERK3 subfamily, comprising the products of two genes, MAPK4 and MAPK6 (14).

AB - The family of mitogen-activated protein kinases (MAPKs) comprises several protein kinases, united by their ability to phosphorylate serine or threonine residues followed by proline; therefore, these often are termed proline-directed protein kinases. Another characteristic feature of the MAPKs is the presence of specific phosphoacceptor site(s) in the regulatory loop of the enzyme catalytic core. HISTORY AND EVOLUTION MAPKs were originally named after the protein they were discovered to phosphorylate in insulin-or growth factor–treated mammalian cells, namely microtubule-associated protein 2 (MAP-2). Later, with the realization that virtually all mitogens lead to the rapid activation of these protein kinases, the enzymes were renamed mitogen-activated protein kinases. Now, it is clear that MAPK function is not limited to the initially described induction of cell division, but also extends to control over cell differentiation, survival, motility, and gene expression. Because MAPKs orchestrate the physiological processes fundamental for both single-and multicellular organisms, it is not surprising that homologous enzymes are found in eukaryotes from budding yeast to mammals (1). The deletion of certain MAPK genes in mammals leads to early embryonic lethality, proving the essential role of MAPK signaling in the developmental processes (Table 81–1). MITOGEN-ACTIVATED PROTEIN KINASE STRUCTURE AND FUNCTION To date, five different groups of MAPKs are known in mammals. Enzymes within groups are generated from a number of gene products; additional isoforms were shown to derive from the alternative splicing of pre-mRNAs (12). Mammalian MAPKs include extracellular-signal-regulated protein kinase (ERK)1/2; p38 MAPKs (α, β, γ, and δ); c-jun N-terminal kinases (JNK1, JNK2, JNK3);ERK5, also known as BMK1(13); and the recently identified ERK3 subfamily, comprising the products of two genes, MAPK4 and MAPK6 (14).

UR - http://www.scopus.com/inward/record.url?scp=84928865437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928865437&partnerID=8YFLogxK

U2 - 10.1017/CBO9780511546198.082

DO - 10.1017/CBO9780511546198.082

M3 - Chapter

SN - 9780511546198

SN - 0521853761

SN - 9780521853767

SP - 737

EP - 745

BT - Endothelial Biomedicine

PB - Cambridge University Press

ER -